Navigation Links
MiMedx Addresses FDA Untitled Letter And Reiterates 2013 And 2014 Guidance
Date:9/4/2013

cember 4, 2012."  The establishment report is posted on the Company's website at www.mimedx.com.

MiMedx is very focused on regulatory compliance and proceeded with marketing the injectable product only after receiving advice from outside legal counsel that the product met the criteria for regulation as an HCT/P under Section 361 of the Public Health Service Act.  The Company believes the FDA's conclusion is based on a misunderstanding of the micronization process and is responding to the Untitled Letter and will reiterate its request for a meeting with the FDA.

The Company reiterated its expected revenue range for 2013 of $54 million to $60 million and its 2014 goal of $90 million to $110 million.  The revenues from the Company's injectable are projected to be approximately  15% of the Company's 2014 revenues. 

Parker H. "Pete" Petit, the Company's  Chairman & CEO, stated, "Based on other precedents,  the Company believes it should be able to continue to sell its injectable products, but even if that not the case, management believes it can refocus its resources to achieve its stated revenue goals."

About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lie
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MiMedx Group, Inc. Announces Release Date for 2013 Second Quarter Results
2. MiMedx Announces 2012 Results
3. MiMedx Group to Present at the 6th Annual OneMedForum
4. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
5. CorePharma Addresses Violations in FDA Warning Letter
6. OrbusNeich Launches Worlds First Dual Therapy Stent That Addresses Challenges of Delayed Coronary Artery Healing Associated with Monotherapy Drug Eluting Stents
7. CVS Caremark CEO Addresses Economic Club of Pittsburgh on Reinventing Pharmacy for Better Health
8. Issue Brief Addresses Stage 2 Meaningful Use Patient Education and Engagement Initiatives
9. Generex Addresses Recent Trading Volume in Shares of its Common Stock
10. ACEP Commends Congress For Passing Legislation That Addresses Drug Shortages As Well As "Bath Salts"
11. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Aufgrund der enormen Nachfrage ... Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre 2014 ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und ... treten. Für international tätige Unternehmen geht ... "ob", sondern darum, "wann" sie die neu in ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Sept. 20 Cellectis bioresearch, the specialist in ... and Helix BioService & Consultants Pvt Ltd (Helix ... for the promotion of Cellectis bioresearch,s meganuclease-based products ... young company comprised of professionals with proven expertise ...
... JOSE, Calif., Sept. 17 Teikoku Pharma USA, Inc., ... U.S. Food and Drug Administration (FDA) has accepted for ... weekly transdermal patch of Aricept®, a leading medication for ... developed the weekly Aricept(r) patch based on a license ...
Cached Medicine Technology:Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 2Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 3FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review 2
(Date:9/19/2014)... Chino Hills, CA (PRWEB) September 19, 2014 ... the fastest-selling fitness boot camp in the country. He’s also ... mentoring thousands of clients, coaching celebrity trainers and serving as ... He knows marketing, and he says that becoming an integral ... camp’s success. , “One of the things that Fit Body ...
(Date:9/19/2014)... FL (PRWEB) September 19, 2014 ... Scott Theirl, a functional neurologist in private practice ... use of Prevagen Professional in older adults with ... Symposium – Focus On Brain Health conference ... Professional is the strongest formula available of the ...
(Date:9/19/2014)... September 19, 2014 ShopRite has launched ... School -- with the 2014-2015 school year. The new ... schools via eBoxTops and special donations throughout the year. ... school by registering their ShopRite Price Plus Card at ... for their favorite school. By using their Price Plus ...
(Date:9/19/2014)... 2014 Atlantic Information Services, Inc. (AIS) ... Directory of Health Plans — is pleased to announce ... 2014-2015. The latest edition of the annual book provides ... care industry. , With valuable intelligence on a ... benefit design and management strategies to corporate financial results ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 B. E. ... to healthcare providers, has been retained to lead a ... John’s Episcopal Hospital in Far Rockaway, N.Y. The top ... Smith has recently placed more than 900 healthcare executives ... a faith-based, full service community hospital serving the Rockaway ...
Breaking Medicine News(10 mins):Health News:New Post from Boot Camp Marketing Expert Bedros Keuilian Explains Importance of Becoming Part of the Community 2Health News:New Post from Boot Camp Marketing Expert Bedros Keuilian Explains Importance of Becoming Part of the Community 3Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2Health News:ShopRite to Donate Up to $1 Million to Local Schools 2Health News:New Book from Atlantic Information Provides Insights Into Trends in the Health Care Industry 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 3
... Holdings,Inc. (NYSE: PAY ) today announced ... with Secure EDI,s state-of-the-art platform to consolidate,patient payments ... Secure EDI is a recognized market ... dental and institutional providers. The,company also creates seamless ...
... Annual Basic and Diluted Net Loss per Share of $1.87- ... or $4.77 per Diluted ShareSILVER SPRING, Md., Feb. 17 ... its financial results for the fourth quarter and year ended ... for 2008 grew in excess of 30% for the seventh ...
... extended as unlisted warrants to May 12, 2009 -BELLEVILLE, ... (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, announced ... the up to 8,203,334 common share purchase warrants issued ... March, 2007. 7,676,554 of these warrants, currently listed for ...
... FLORHAM PARK, N.J., Feb. 17 Shionogi & Co, ... velneperit, a novel neuropeptide Y (NPY) Y5 receptor antagonist ... of demonstrating a statistically significant reduction in body weight. ... the NPY Y5 receptor as a target for obesity ...
... 17 PAREXEL Consulting, a business unit ... leading global consultancy serving the biopharmaceutical and medical device ... of Principal Consultant in its European Product Development Practice. ... Sweden,s Medical Products Agency (MPA), will advise clients on ...
... N.Y., Feb. 17 New paintbrush makes painting ... ArroWorthy Co. NY, is designed to match the ... handle allows a variety of gripping areas for ... incorporated for on job resting or storage. White ...
Cached Medicine News:Health News:Secure EDI Integrates VeriFone IPCharge in Real Time Patient Payment and Claims Processing Solutions Suite 2Health News:Secure EDI Integrates VeriFone IPCharge in Real Time Patient Payment and Claims Processing Solutions Suite 3Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 2Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 3Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 4Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 5Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 6Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 7Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 8Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 9Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 10Health News:Bioniche Warrants' Expiration Date to be Extended 2Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 2Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 3Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 4Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 5Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 6Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 2Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 3Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 4Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 5Health News:Efficient and Comfortable, the Right Brush(R) is the First Revolution in Painting Since the Roller 2Health News:Efficient and Comfortable, the Right Brush(R) is the First Revolution in Painting Since the Roller 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: